shutterstock_274590824

Biogen stock surges following patent victory over Mylan for Tecfidera

pharmafile | February 6, 2020 | News story | Sales and Marketing |  Biogen, Mylan, multiple sclerosis, pharma, tecfidera 

Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a big win for the US firm.

The ruling means that Biogen maintain its exclusive rights to the drug until 2028. The Patent Trial and Appeal Board of the US Patent and Trademark Office judged that Mylan’s challenge had “not demonstrated by a preponderance of the evidence the unpatentability of claims”.

Biogen’s share value rocketed by 32% in the wake of the news. The gravity of the win can’t be overstated – Tecfidera brought in $4.43 billion last year, amounting to 30.8% of Biogen’s total revenue

While Biogen was reportedly pleased with the ruling, Mylan was unsurprisingly unhappy, with a company spokesperson noting that the firm “strongly disagrees with the decision and plans to pursue all available options for appeal.”

Advertisement

“Mylan continues to believe, based on the law and the facts, that Biogen’s ‘514 patent is invalid and will continue its challenges in both the district court and the Federal Circuit to remove this patent from blocking generic competition to Tecfidera,” they continued.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy

Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose …

The Gateway to Local Adoption Series

Latest content